세계의 바이오프로세스 기술 시장 : 제품별, 용도별, 최종사용자별, 지역 범위별, 예측

Bioprocess Technology Market Size And Forecast

Bioprocess Technology Market size was valued at USD 28.7 Billion in 2024 and is projected to reach USD 60.3 Billion by 2032, growing at a CAGR of 10.70% from 2026 to 2032.

Bioprocess technology refers to the use of living cells or their components to develop products and processes that enhance the production of biological materials.

This technology is pivotal in various applications, including the production of pharmaceuticals, enzymes, biofuels, and food products, as it leverages biological systems for efficiency and sustainability.

The future of bioprocess technology is promising, driven by advancements in synthetic biology, genomics, and automation, which are expected to lead to more efficient production methods and innovative applications in fields such as personalized medicine, renewable energy, and sustainable agriculture.

Global Bioprocess Technology Market Dynamics

The key market dynamics that are shaping the global bioprocess technology market include:

Key Market Drivers:

Growing Demand for Biopharmaceuticals: The biopharmaceutical sector is expanding rapidly, driven by the increasing prevalence of chronic diseases and advancements in personalized medicine. According to the Global Biopharmaceutical Market Report 2023, the market is expected to reach USD 3.8 trillion by 2025, growing at a compound annual growth rate (CAGR) of 8.6%.

Advancements in Biotechnology: Innovations in biotechnology, including gene editing and synthetic biology, are enhancing the efficiency and productivity of bioprocesses. A report from the National Institute of Health (NIH) highlights those investments in biotechnology research and development reached approximately USD 65 billion in 2021, indicating a strong commitment to technological advancements in this field.

Increasing Focus on Sustainability: There is a growing emphasis on sustainable practices in various industries, particularly in the production of biofuels and biodegradable materials. The International Renewable Energy Agency (IRENA) reports that the global biofuels market is projected to grow at a CAGR of 6.5%, reaching USD 185 billion by 2027.

Government Support and Funding: Many governments worldwide are providing substantial funding and incentives to support bioprocess technology development. For instance, the U.S. Department of Energy (DOE) announced an investment of USD 57 million in 2023 to advance bioenergy technologies, reflecting strong governmental backing for bioprocess innovations.

Key Challenges:

Regulatory Hurdles: The bioprocess technology sector faces complex regulatory requirements that can delay product approvals and increase costs. Navigating these regulations requires significant time and resources.

High Production Costs: The initial investment for bioprocess technology, including equipment and raw materials, can be substantial, leading to high production costs that may hinder market entry for smaller companies.

Scalability Issues: Transitioning from laboratory-scale processes to commercial-scale production can pose challenges, including maintaining product quality and consistency during scale-up.

Talent Shortage: There is a growing demand for skilled professionals in bioprocessing, but a shortage of qualified personnel can limit innovation and development within the industry.

Key Trends:

Integration of Automation and AI: The increasing use of automation and artificial intelligence in bioprocessing is enhancing efficiency, reducing human error, and enabling real-time monitoring and optimization of processes.

Shift towards Continuous Processing: There is a trend toward continuous bioprocessing, which offers advantages over traditional batch processing, such as reduced production time and improved product quality.

Focus on Personalized Medicine: The rise of personalized medicine is driving innovation in bioprocess technology, leading to the development of tailored therapies that meet individual patient needs.

Sustainable Practices and Green Technologies: The industry is increasingly adopting sustainable practices and green technologies, such as using renewable resources and minimizing waste, to align with global sustainability goals.

Global Bioprocess Technology Market Regional Analysis

Here is a more detailed regional analysis of the global bioprocess technology market:

North America:

North America is the dominant region in the global bioprocess technology market, driven by its advanced biotechnology infrastructure, robust research and development initiatives, and strong presence of major pharmaceutical companies. The region is home to a large number of biopharmaceutical firms that invest heavily in innovative bioprocessing technologies. According to a report by the Biotechnology Innovation Organization (BIO), the U.S. biopharmaceutical sector generated over $300 billion in revenue in 2023, highlighting the significant economic impact of bioprocess technologies.

Additionally, government initiatives and funding have further supported the growth of the bioprocess technology sector. For instance, the National Institutes of Health (NIH) has allocated approximately $50 billion annually to support biomedical research, including advancements in bioprocessing technologies. This financial backing encourages the development and commercialization of new biopharmaceutical products, reinforcing North America's leadership in the market.

Asia Pacific:

The Asia Pacific region is the fastest-growing market for bioprocess technology, driven by rapid industrialization, increasing healthcare demands, and significant investments in biotechnology. Countries like China and India are emerging as key players due to their growing biopharmaceutical sectors and expanding manufacturing capabilities. According to a report by the Asian Development Bank (ADB), the biotechnology market in Asia is projected to grow at a CAGR of over 15% from 2024 to 2030, underscoring its rapid expansion.

Additionally, the supportive government policies in countries like China, which includes the "Made in China 2025" initiative aimed at enhancing the biotechnology sector, are propelling market growth. The increasing focus on research and development in bioprocess technologies to meet the rising demand for biologics and biosimilars is further driving this growth trajectory in the Asia Pacific region.

Global Bioprocess Technology Market: Segmentation Analysis

The Global Bioprocess Technology Market is segmented on the basis of Product, Application, End User, and Geography.

Bioprocess Technology Market, By Product

• Bioprocess Instruments
• Bioprocess Services

Based on Product, the Global Bioprocess Technology Market is segmented into Bioprocess Instruments and Bioprocess Services. The bioprocess instruments is the dominating segment, driven by the demand for advanced equipment such as bioreactors, fermenters, and analytical tools essential for biopharmaceutical production and research. However, the bioprocess services segment is the fastest growing, fueled by the increasing complexity of bioprocesses and the need for outsourcing specialized services like cell line development, process optimization, and regulatory compliance.

Bioprocess Technology Market, By Application

• Pharmaceuticals
• Biotechnology
• Food and Beverage
• Environmental Management

Based on Application, the Global Bioprocess Technology Market is segmented into Pharmaceuticals, Biotechnology, Food and Beverage and Environmental Management. The pharmaceuticals is the dominating segment, driven by high demand for biopharmaceuticals and advanced therapies. However, the biotechnology segment is the fastest-growing, propelled by innovations in genetic engineering, personalized medicine, and vaccine development.

Bioprocess Technology Market, By End User

• Biopharmaceutical Companies
• Academic and Research Institutes
• Contract Manufacturing Organizations

Based on End User, the Global Bioprocess Technology Market is segmented into Biopharmaceutical Companies, Academic and Research Institutes and Contract Manufacturing Organizations. Biopharmaceutical companies dominate the landscape, as they represent a significant portion of the overall market due to their substantial investments in research and development for drug production. However, the contract manufacturing organizations (CMOs) segment is witnessing the fastest growth, driven by the increasing trend of outsourcing production processes by biopharmaceutical companies looking to reduce costs and improve efficiency.

Bioprocess Technology Market, By Geography

• North America
• Europe
• Asia Pacific
• Rest of the World

Based on the Geography, the Global Bioprocess Technology Market are classified into North America, Europe, Asia Pacific, and Rest of World. North America is the dominant region in the global bioprocess technology market, driven by its advanced biotechnology infrastructure, robust research and development initiatives, and strong presence of major pharmaceutical companies. The Asia Pacific region is the fastest-growing market for bioprocess technology, driven by rapid industrialization, increasing healthcare demands, and significant investments in biotechnology.

Key Players

The "Global Bioprocess Technology Market" study report will provide valuable insight with an emphasis on the global market. The major players in the market are Thermo Fisher Scientific Inc., Sartorius AG, Merck KGaA, Danaher Corporation, General Electric Company (GE Healthcare), Eppendorf AG, Lonza Group Ltd., Becton, Dickinson and Company.

Our market analysis also entails a section solely dedicated to such major players wherein our analysts provide an insight into the financial statements of all the major players, along with its product benchmarking and SWOT analysis. The competitive landscape section also includes key development strategies, market share, and market ranking analysis of the above-mentioned players globally.

• Global Bioprocess Technology Market: Recent Developments
• In August 2024 Merck KGaA announced a strategic partnership with Pfizer to enhance the bioprocessing capabilities for monoclonal antibody production. This collaboration aims to leverage Merck's advanced bioprocess technology platforms to improve efficiency and scalability in drug development.
• In July 2024 Thermo Fisher Scientific opened a new bioprocessing facility in Massachusetts, aimed at expanding its production capacity for cell culture media and other bioprocessing solutions.
• In June 2024 Sartorius completed the acquisition of a bioprocessing technology startup that specializes in cell culture systems. This acquisition aligns with Sartorius's strategy to strengthen its portfolio of innovative solutions for biopharmaceutical manufacturing.

TABLE OF CONTENTS

1 INTRODUCTION

• 1.1 MARKET DEFINITION
• 1.2 MARKET SEGMENTATION
• 1.3 RESEARCH TIMELINES
• 1.4 ASSUMPTIONS
• 1.5 LIMITATIONS

2 RESEARCH METHODOLOGY

• 2.1 DATA MINING
• 2.2 SECONDARY RESEARCH
• 2.3 PRIMARY RESEARCH
• 2.4 SUBJECT MATTER EXPERT ADVICE
• 2.5 QUALITY CHECK
• 2.6 FINAL REVIEW
• 2.7 DATA TRIANGULATION
• 2.8 BOTTOM-UP APPROACH
• 2.9 TOP-DOWN APPROACH
• 2.10 RESEARCH FLOW
• 2.11 DATA SOURCES
• 2.12 KEY INSIGHTS FROM INDUSTRY EXPERTS

3 EXECUTIVE SUMMARY

• 3.1 MARKET OVERVIEW
• 3.2 GLOBAL BIOPROCESS TECHNOLOGY ECOLOGY MAPPING
• 3.3 GLOBAL BIOPROCESS TECHNOLOGY MARKET ATTRACTIVENESS
• 3.4 GLOBAL BIOPROCESS TECHNOLOGY ABSOLUTE MARKET OPPORTUNITY
• 3.5 GLOBAL BIOPROCESS TECHNOLOGY MARKET GEOGRAPHICAL INSIGHTS
• 3.6 GLOBAL BIOPROCESS TECHNOLOGY MARKET, BY TYPE(USD MILLION)
• 3.7 GLOBAL BIOPROCESS TECHNOLOGY MARKET, BY APPLICATION (USD MILLION)
• 3.8 GLOBAL BIOPROCESS TECHNOLOGY MARKET, BY END USER (USD MILLION)
• 3.9 FUTURE MARKET OPPORTUNITIES
• 3.10 GLOBAL MARKET SPLIT

4 MARKET OUTLOOK

• 4.1 GLOBAL BIOPROCESS TECHNOLOGY MARKET OUTLOOK
• 4.2 MARKET DRIVERS
  • 4.2.1 RISE IN DISEASE BURDEN.
  • 4.2.2 ONGOING TREND OF OUTSOURCING OF BIOPROCESS DEVELOPMENT
• 4.3 MARKET RESTRAINT
  • 4.3.1 HIGH CAPITAL INVESTMENT AND HIGH COST OF INSTRUMENTS
  • 4.3.2 STRINGENT GOVERNMENT REGULATIONS.
• 4.4 OPPORTUNITIES
  • 4.4.1 RISE IN RESEARCH AND DEVELOPMENT INVESTMENT FOR BIOTECHNOLOGY
  • 4.4.2 ROBUST BIOPHARMACEUTICAL PIPELINE
• 4.5 IMPACT OF COVID19 ON THE GLOBAL MARKET
• 4.6 PORTER'S FIVE FORCES ANALYSIS
  • 4.6.1 THREAT OF NEW ENTRANTS
  • 4.6.2 THREAT OF SUBSTITUTES
  • 4.6.3 BARGAINING POWER OF SUPPLIERS
  • 4.6.4 BARGAINING POWER OF BUYERS
  • 4.6.5 INTENSITY OF COMPETITIVE RIVALRY
• 4.7 MACROECONOMIC ANALYSIS
• 4.8 VALUE CHAIN ANALYSIS

5 MARKET, BY PRODUCT

• 5.1 OVERVIEW
• 5.2 Bioprocess Instruments
• 5.3 Bioprocess Services

6 MARKET, BY APPLICATION

• 6.1 OVERVIEW
• 6.2 Pharmaceuticals
• 6.3 Biotechnology
• 6.4 Food and Beverage
• 6.5 Environmental Management

7 MARKET, BY END-USER

• 7.1 OVERVIEW
• 7.2 Biopharmaceutical Companies
• 7.3 Academic and Research Institutes
• 7.4 Contract Manufacturing Organizations

8 MARKET, BY GEOGRAPHY

• 8.1 OVERVIEW
• 8.2 NORTH AMERICA
  • 8.2.1 NORTH AMERICA MARKET SNAPSHOT
  • 8.2.2 U.S.
  • 8.2.3 CANADA
  • 8.2.4 MEXICO
• 8.3 EUROPE
  • 8.3.1 EUROPE MARKET SNAPSHOT
  • 8.3.2 GERMANY
  • 8.3.3 U.K.
  • 8.3.4 FRANCE
  • 8.3.5 ITALY
  • 8.3.6 SPAIN
  • 8.3.7 REST OF EUROPE
• 8.4 ASIA PACIFIC
  • 8.4.1 ASIA PACIFIC MARKET SNAPSHOT
  • 8.4.2 CHINA
  • 8.4.3 JAPAN
  • 8.4.4 INDIA
  • 8.4.5 REST OF APAC
• 8.5 LATIN AMERICA
  • 8.5.1 LATIN AMERICA MARKET SNAPSHOT
  • 8.5.2 BRAZIL
  • 8.5.3 ARGENTINA
  • 8.5.4 REST OF LATIN AMERICA
• 8.6 MIDDLE EAST AND AFRICA
  • 8.6.1 MIDDLE EAST AND AFRICA MARKET SNAPSHOT
  • 8.6.2 UAE
  • 8.6.3 SAUDI ARABIA
  • 8.6.4 SOUTH AFRICA
  • 8.6.5 REST OF MIDDLE EAST AND AFRICA

9 COMPETITIVE LANDSCAPE

• 9.1 OVERVIEW
• 9.2 COMPETITIVE SCENARIO
• 9.3 COMPANY MARKET RANKING ANALYSIS
• 9.4 COMPANY REGIONAL FOOTPRINT
• 9.5 COMPANY INDUSTRY FOOTPRINT
• 9.6 ACE MATRIX
  • 9.6.1 ACTIVE
  • 9.6.2 CUTTING EDGE
  • 9.6.3 EMERGING
  • 9.6.4 INNOVATORS

10 COMPANY PROFILES

• 10.1 GE HEALTHCARE COMPANY
  • 10.1.1 COMPANY OVERVIEW
  • 10.1.2 COMPANY INSIGHTS
  • 10.1.3 SEGMENT BREAKDOWN
  • 10.1.4 PRODUCT BENCHMARKING
  • 10.1.5 KEY DEVELOPMENTS
  • 10.1.6 SWOT ANALYSIS
  • 10.1.7 WINNING IMPERATIVES
  • 10.1.8 CURRENT FOCUS & STRATEGIES
  • 10.1.9 THREAT FROM COMPETITION
• 10.2 THERMO FISHER SCIENTIFIC
  • 10.2.1 COMPANY OVERVIEW
  • 10.2.2 COMPANY INSIGHTS
  • 10.2.1 SEGMENT BREAKDOWN
  • 10.2.2 PRODUCT BENCHMARKING
  • 10.2.3 KEY DEVELOPMENTS
  • 10.2.4 WINNING IMPERATIVES
  • 10.2.5 CURRENT FOCUS & STRATEGIES
  • 10.2.6 THREAT FROM COMPETITION
  • 10.2.7 SWOT ANALYSIS
• 10.3 DANAHER CORPORATION
  • 10.3.1 COMPANY OVERVIEW
  • 10.3.2 COMPANY INSIGHTS
  • 10.3.3 SEGMENT BREAKDOWN
  • 10.3.4 PRODUCT BENCHMARKING
  • 10.3.5 WINNING IMPERATIVES
  • 10.3.6 CURRENT FOCUS & STRATEGIES
  • 10.3.7 THREAT FROM COMPETITION
  • 10.3.8 SWOT ANALYSIS
• 10.4 LCG GROUP
  • 10.4.1 COMPANY OVERVIEW
  • 10.4.2 COMPANY INSIGHTS
  • 10.4.3 PRODUCT BENCHMARKING
• 10.5 MERCK GROUP
  • 10.5.1 COMPANY OVERVIEW
  • 10.5.2 COMPANY INSIGHTS
  • 10.5.3 SEGMENT BREAKDOWN
  • 10.5.4 PRODUCT BENCHMARKING
• 10.6 LONZA GROUP AG
  • 10.6.1 COMPANY OVERVIEW
  • 10.6.2 COMPANY INSIGHTS
  • 10.6.3 SEGMENT BREAKDOWN
  • 10.6.4 PRODUCT BENCHMARKING
• 10.7 SARTORIUS AG.
  • 10.7.1 COMPANY OVERVIEW
  • 10.7.2 COMPANY INSIGHTS
  • 10.7.3 SEGMENT BREAKDOWN
  • 10.7.4 PRODUCT BENCHMARKING
• 10.8 CORNING INCORPORATED
  • 10.8.1 COMPANY OVERVIEW
  • 10.8.2 COMPANY INSIGHTS
  • 10.8.3 SEGMENT BREAKDOWN
  • 10.8.4 PRODUCT BENCHMARKING
• 10.9 BIO-RAD LABORATORIES, INC.
  • 10.9.1 COMPANY OVERVIEW
  • 10.9.2 COMPANY INSIGHTS
  • 10.9.3 SEGMENT BREAKDOWN
  • 10.9.4 PRODUCT BENCHMARKING